WallStSmart

Basel Medical Group Ltd Ordinary Shares (BMGL)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 446205% more annual revenue ($65.77B vs $14.74M). MRK leads profitability with a 13.6% profit margin vs -68.2%. MRK earns a higher WallStSmart Score of 50/100 (D+).

BMGL

Hold

38

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 3/9Altman Z: -1.69

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BMGL.

MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$129.79

$48.56 premium

UndervaluedFair: $81.23Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BMGL2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
67.1%10/10

Revenue surging 67.1% year-over-year

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

BMGL4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$8.80M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.573/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BMGL

The strongest argument for BMGL centers on Revenue Growth, Price/Book. Revenue growth of 67.1% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : BMGL

The primary concerns for BMGL are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.57 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

BMGL profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

BMGL is growing revenue faster at 67.1% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 38/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Basel Medical Group Ltd Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Basel Medical Group Ltd provides healthcare services. The company is headquartered in Singapore.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?